American Association of Pharmaceutical Sciences - AAPS PharmSci 360
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to American Association of Pharmaceutical Sciences - AAPS PharmSci 360 — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
About this event
AAPS PharmSci 360 (American Association of Pharmaceutical Scientists) — Event Overview Description
AAPS PharmSci 360 is the American Association of Pharmaceutical Scientists’ 2026 annual meeting, scheduled for October 25–28, 2026. The conference will take place at the Ernest N. Morial Convention Center in New Orleans, LA, United States.
This event is designed for professionals advancing pharmaceutical science across preclinical and translational stages of drug development. The program emphasizes the integration of modern quantitative and predictive methods—spanning in vitro experimentation, in silico modeling, and data-driven approaches—so research teams can strengthen translation of mechanistic insights into human-relevant decision-making.
Primary Scientific Focus Areas
The meeting programming is organized around three detailed thematic tracks. Collectively, these themes highlight how teams combine experimental evidence with quantitative modeling and real-world clinical insights to improve predictability, translational continuity, and decision quality across the drug development pipeline.
Theme 1: Integrating In Vitro Data with In Silico and Quantitative Modeling Approaches
Theme 1 focuses on how in vitro datasets can be combined with in silico tools and quantitative pharmacology to drive translational decisions.
Key topics include:
In Vitro ADME, drug enzymes and transporters, target engagement, drug discovery and lead optimization,
IVIVE (in vitro–in vivo extrapolation), mechanistic and static modeling, and quantitative approaches such as
PBPK modeling and QSP (quantitative systems pharmacology).
The theme also highlights decision frameworks for translational consistency, including drug-drug interaction assessment (DDI),
human dose projection, and emerging methods such as AI/ML, physiologically relevant in vitro systems, and early applications
of digital twins.
Theme 2: Innovative Preclinical and Translational Strategies to Enhance Predictability
Theme 2 centers on improving predictability through advanced preclinical and translational strategies, including:
preclinical development and translational science; predictive models and disease-relevant modeling; and
New Approach Methodologies (NAMs) such as organ-on-a-chip and microphysiological systems.
It also covers translational biomarkers, quantitative PK/PD, and biologically informed digital twins, supported by mechanistic disease modeling.
This track addresses systems pharmacology, model-based translation, human relevance, and evolving regulatory-science perspectives.
Theme 3: Integrating Clinical Trials, Real-World Data, MIDD, and AI/ML
Theme 3 addresses how advanced analytics and evidence integration can transform clinical development and evaluation. The listed focus areas include clinical trials, real-world data (RWD), and model-informed drug development (MIDD), with strong emphasis on AI/ML in clinical development. Additional highlighted topics include trial design, dose optimization, and patient-centric approaches.
Why This Meeting Matters for Pharmaceutical Science Teams
PharmSci 360 is structured to support cross-disciplinary integration—connecting scientific methods and decision frameworks across preclinical, translational, and clinical development. The themes encourage continuity from bench to human application, with an explicit focus on reducing uncertainty in translation and improving the quality of early scientific decisions.
For organizations working in areas such as in vitro/in vivo translation, model-informed analytics, translational biomarkers, predictive modeling, and data-driven clinical evaluation, AAPS PharmSci 360 provides a concentrated technical environment to align research strategy, share innovations, and advance methodologies that support successful drug development.
Event Details (Confirmed from Official Listing)
- Event: AAPS PharmSci 360 (AAPS 2026 PharmSci 360)
- Date: October 25–28, 2026
- Venue: Ernest N. Morial Convention Center
- City/State: New Orleans, LA
- Country: United States
- Event Type (by content alignment): Pharmaceutical science conference covering preclinical and translational research, modeling, and clinical development
If you’d like, share the target buyer industries and the specific product use-case for your client, and we can map the best-matching attendee segments and the most relevant job profiles aligned to PharmSci 360’s thematic tracks.
Data sheet
| Event Name | AAPS 2026 PharmSci 360 |
| Event Date | October 25–28, 2026 |
| Event Status | Upcoming |
| Venue | Ernest N. Morial Convention Center |
| City | New Orleans |
| State / Region | Louisiana |
| Country | United States |
| Organizer | American Association of Pharmaceutical Scientists (AAPS) |
| Official Event Website | aaps.org/aaps/pharmsci/annual-meeting |
| Event Type | Scientific conference, annual meeting, exhibition, sponsor and poster-based industry event |
| Primary Category | Medical & Pharma |
| Secondary Applicable Categories | Science & Research; IT & Technology |
| Audience Reach | National, with likely international scientific and industry participation |
| Estimated Attendance / Expected Footfall | Attendance figure not publicly confirmed by the organizer. |
| Attendance Data Reliability | Low for attendance size; organizer has confirmed dates, venue, location, registration, exhibitor/sponsor activity, programming themes, and abstract/poster activity. |
| Main Purpose of Event | To convene pharmaceutical scientists, R&D teams, translational researchers, clinical development professionals, modeling experts, exhibitors, sponsors, and related stakeholders around drug discovery, development, translational science, clinical evaluation, and enabling technologies. |
AAPS PharmSci 360 is the annual scientific meeting of the American Association of Pharmaceutical Scientists. The official 2026 event page confirms the meeting will take place October 25–28, 2026 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The published program themes position the event around preclinical and translational sciences, in vitro and in silico integration, PBPK and QSP modeling, AI/ML, clinical trials, real-world data, and model-informed drug development.
From a commercial and attendee-profiling perspective, this is a high-value pharma-science event for identifying research, development, translational medicine, formulation, regulatory science, and clinical-development stakeholders. It is particularly relevant for suppliers supporting drug development workflows, analytical platforms, modeling software, lab technologies, bio/pharma services, outsourced development, and scientific collaboration. Procurement activity is likely to be specialized rather than mass-market, with strong influence from technical evaluators, lab leaders, development scientists, and innovation-driven decision makers.
| Buyer / Attendee Segment | Typical Organizations | Buying Role or Influence | Relevance to Exhibitors / Suppliers |
|---|---|---|---|
| Pharmaceutical R&D leaders | Branded pharma, specialty pharma, drug developers | High influence on platform selection, scientific partnerships, and outsourced studies | Core buyer group for drug development tools, scientific services, and translational technologies |
| Preclinical and translational scientists | Pharma, biotech, CROs, academic centers | Technical evaluators and specification setters | Important for assay systems, organ-on-chip, biomarker, modeling, and translational research offerings |
| Clinical development and MIDD teams | Drug sponsors, clinical-stage biotech, development organizations | Influence trial design, dose optimization, data integration, and vendor selection | Relevant for clinical analytics, trial tech, simulation tools, and real-world data solutions |
| Quantitative modeling and PK/PD experts | Pharma, biotech, software-enabled science teams, consulting groups | Strong influence on computational tool adoption and modeling partnerships | High relevance for PBPK, QSP, AI/ML, simulation, and scientific computing vendors |
| Formulation and CMC professionals | Drug product development teams, CDMOs, applied research labs | Influence material sourcing, equipment choices, and process-development services | Relevant for formulation technologies, analytical instrumentation, and development support |
| Regulatory science professionals | Industry regulatory teams, standards bodies, regulatory-facing scientific groups | Influence evidence standards and adoption risk | Important for solutions that require validation, compliance, and scientific defensibility |
| Procurement and sourcing teams | Large pharma, biotech platforms, CROs, research institutions | Commercial buyers, contract owners, vendor onboarding stakeholders | Relevant for enterprise purchases, preferred vendor agreements, and lab service contracts |
| Academic and research institution investigators | Universities, medical schools, translational research institutes | Influence grants, collaborations, and pilot evaluations | Good fit for scientific tools, software, data platforms, and co-development partnerships |
| CRO and CDMO business development teams | Contract research and manufacturing organizations | Partnership buyers and channel multipliers | Useful for outsourced development, white-label delivery, and referral channels |
| Scientific software and innovation leaders | Digital R&D groups, data science teams, computational biology units | Strong influence on AI/ML, data integration, and analytics procurement | Relevant for informatics, cloud platforms, scientific AI, and integration services |
| Geographic Area | Likely Attendee Origin | Buyer Concentration | Notes |
|---|---|---|---|
| Host city | New Orleans | Moderate local concentration | Venue supports conference-scale scientific events; local attendance likely includes regional academic and healthcare research stakeholders. |
| Host state / region | Louisiana and Gulf South | Moderate regional concentration | Likely draw from Louisiana, Texas, Mississippi, Alabama, and nearby Southeastern markets. |
| Nearby business hubs | Houston, Dallas-Fort Worth, Atlanta, Research Triangle, Nashville | High for pharma-adjacent travel markets | Likely attendee origins based on accessibility and biopharma, CRO, academic, and clinical research ecosystems. |
| National reach | United States-wide | High | Confirmed as an AAPS annual meeting; national scientific society events typically attract broad U.S. participation across industry, academia, and research organizations. |
| International reach | Likely select participation from global pharma and research markets | Medium | Likely attendee profile. International attendance is plausible for pharmaceutical science meetings, but current-year country mix is not publicly confirmed in the supplied official text. |
| Reach Level | Assessment | Explanation |
|---|---|---|
| National | Primary classification | The event is the annual meeting of a U.S.-based professional association and is positioned around industry-wide scientific themes relevant to pharmaceutical R&D, translational medicine, and clinical development. |
| Global | Secondary likely reach | Pharmaceutical science topics such as PBPK, QSP, AI/ML, clinical development, and translational science are globally relevant, but the current-year international attendee footprint is not officially quantified in the supplied material. |
| Buyer Company / Organization | Buyer Type | Why It Is Relevant | Website | Best Job Titles to Target | Evidence Level |
|---|---|---|---|---|---|
| Verified current-year buyer-side organization list not publicly identified in supplied official materials | Data availability note | The supplied official event page confirms registration, exhibits/sponsorship, program themes, and abstracts/posters, but does not provide a buyer, attendee, speaker-organization, sponsor, or exhibitor company list in the provided source text. | aaps.org | Procurement Manager; Director R&D; Translational Sciences Director; Clinical Development Director; Scientific Affairs Lead | Confirmed current-year event details only; participant organizations not publicly verified in supplied content |
| Priority | Job Title / Function | Department | Seniority Level | Why This Role Matters |
|---|---|---|---|---|
| 1 | VP, Pharmaceutical Sciences | R&D | VP | Executive sponsor for scientific platforms, outsourcing, and strategic innovation. |
| 2 | Director, Translational Sciences | Translational Research | Director | High-fit role for preclinical-to-clinical decision tools and translational services. |
| 3 | Director, Clinical Pharmacology | Clinical Development | Director | Relevant for PK/PD, dose optimization, DDI assessment, and MIDD workflows. |
| 4 | Head of Modeling & Simulation | Quantitative Sciences | Director / Head | Directly aligned with PBPK, QSP, AI/ML, and predictive modeling themes. |
| 5 | Director, Drug Metabolism & Pharmacokinetics | Preclinical Development | Director | Important evaluator for ADME, IVIVE, DDI, and related enabling technologies. |
| 6 | Scientific Procurement Manager | Procurement / Strategic Sourcing | Manager | Commercial owner for scientific services, instruments, and enterprise contracts. |
| 7 | Director, Formulation Development | CMC / Product Development | Director | Relevant for drug product innovation, process development, and applied formulation tools. |
| 8 | Associate Director, Biomarkers | Translational Medicine | Director / Senior Manager | Key for translational evidence generation and disease-relevant model selection. |
| 9 | Director, Regulatory Science | Regulatory Affairs | Director | Useful for solutions that require acceptance within regulatory-facing development pathways. |
| 10 | Business Development Director | Partnerships / Alliances | Director | Important for co-development, partnering, and outsourced scientific service relationships. |
| Priority | Apollo Industry | Why It Fits the Event | Best Buyer Use Case |
|---|---|---|---|
| 1 | Pharmaceuticals | Direct event fit for drug development and pharmaceutical science. | Enterprise scientific buyers and program leaders. |
| 2 | Biotechnology | Strong fit for translational, preclinical, and clinical-stage innovation companies. | Platform evaluation, outsourced studies, analytics, and data systems. |
| 3 | Research | Highly relevant for translational institutes and scientific organizations. | Collaborative research, grants, and pilot programs. |
| 4 | Higher Education | Academic drug discovery and pharmaceutical science labs are likely attendee segments. | Lab tools, software, and sponsored research relationships. |
| 5 | Hospital & Health Care | Relevant for translational medicine, clinical research, and health-system research units. | Clinical collaboration and real-world data initiatives. |
| 6 | Medical Devices | Selective fit for enabling instrumentation and research systems. | Analytical, bioengineering, and translational lab technologies. |
| 7 | Information Technology & Services | AI/ML, data integration, and scientific informatics themes are prominent. | Scientific data platforms, integration, and digital transformation. |
| 8 | Computer Software | Relevant for modeling, simulation, analytics, and scientific workflow software. | PBPK/QSP tools, trial analytics, and AI-enabled science platforms. |
| 9 | Management Consulting | Useful for specialized life-science consulting and scientific advisory firms. | Advisory services, transformation, and outsourced expertise. |
| 10 | Government Administration | Selective fit where public-sector scientific or regulatory bodies participate. | Regulatory science and scientific collaboration use cases. |
| Metric | Figure | Status | Source / Basis | Notes |
|---|---|---|---|---|
| Estimated total footfall | Attendance figure not publicly confirmed by the organizer. | Unconfirmed | Official event page supplied by user | No attendance number stated in supplied official text. |
| Exhibitor count | Not publicly confirmed in supplied source text | Unconfirmed | Official navigation references “2026 Exhibitor/Sponsor” | Exhibitor/sponsor participation is confirmed as an event component, but no count is visible in the provided content. |
| Buyer count | Not publicly confirmed | Unconfirmed | No buyer count published in supplied official text | Event is science-led; buyer activity is likely embedded within attendee roles rather than reported as a separate hosted-buyer metric. |
| Speaker count | Not publicly confirmed in supplied source text | Unconfirmed | Official page references 2026 Program | Themes are published, but no speaker count is visible in the provided content. |
| Sponsor count | Not publicly confirmed in supplied source text | Unconfirmed | Official page references Exhibitors & Sponsors | Sponsor activity confirmed as a program component only. |
| Historical attendance | Not available from supplied official content | Unavailable | No prior-year attendance data included in provided source text | No historical numeric evidence used to avoid unsupported estimates. |
| Focus Area | Typical Buyer Need | Buyer Engagement Opportunity | Relevant Supplier Offering |
|---|---|---|---|
| Preclinical development | Improve compound selection and development predictability | Scientific demos, case studies, pilot collaborations | Preclinical platforms, ADME services, translational assays, CRO services |
| Translational science | Reduce preclinical-to-human uncertainty | Method validation, proof-of-concept studies, biomarker strategy discussions | Biomarker tools, organ-on-chip, microphysiological systems, translational consulting |
| Modeling and simulation | Better dose prediction, DDI assessment, and mechanistic insight | Solution workshops, technical evaluations, software trials | PBPK, QSP, PK/PD, mechanistic modeling software and consulting |
| AI | Accelerate discovery and improve decision frameworks | Innovation briefings, data integration pilots, workflow modernization | AI/ML platforms, predictive analytics, scientific data engineering |
| Clinical development | Optimize trial design, evidence quality, and development efficiency | Clinical operations and analytics conversations | Clinical development services, trial analytics, data platforms |
| Real-world data | Integrate RWD into development and evaluation strategies | Evidence strategy consultations and data sourcing partnerships | RWD platforms, analytics providers, evidence-generation services |
| Regulatory science | Increase confidence in scientifically acceptable methods | Validation and compliance-centered engagement | Regulatory strategy, documentation support, evidence and quality systems |
| Scientific partnerships | Access external expertise and accelerate specialized workstreams | Alliance building and vendor qualification discussions | CRO/CDMO services, strategic consulting, software-enabled services |
| Factor | Assessment | Explanation |
|---|---|---|
| Buyer relevance | High | The event themes directly align with pharmaceutical R&D, translational science, modeling, and clinical development buyers. |
| Decision-maker availability | High | Association-led scientific events typically attract director-level and above technical decision influencers alongside procurement stakeholders. |
| Data collection potential | Medium | Good for persona mapping and exhibitor/sponsor outreach; weaker for confirmed attendee-list extraction from the supplied source alone. |
| Apollo targeting potential | Very High | The event maps cleanly to Pharmaceuticals, Biotechnology, Research, Higher Education, and scientific software-related buying roles. |
| Geographic targeting potential | High | Best handled through U.S. national life-sciences clusters rather than only local event geography. |
| Best outreach approach | High | Use science-led, use-case messaging tied to modeling, translational predictability, clinical evidence, or workflow acceleration. |
| Overall lead quality | High | Strong fit for specialized B2B pharma-science outreach, especially for high-value solutions and consultative sales. |
| Best use case | High | Ideal for targeted account-based prospecting, sponsor/exhibitor outreach, and scientific buyer persona development. |
| Limitations / risks | Medium | Current-year attendee organizations and attendance figures are not confirmed in the supplied official content, so confirmed attendee-list claims should be avoided. |
| Filter Type | Recommended Filters | Purpose |
|---|---|---|
| Apollo industries | Pharmaceuticals; Biotechnology; Research; Higher Education; Hospital & Health Care; Medical Devices; Information Technology & Services; Computer Software | Capture the most event-relevant buyer pools. |
| Departments | Research; Engineering; Information Technology; Operations; Procurement; Business Development | Covers technical evaluators, budget owners, and partnership leads. |
| Seniority | Director; VP; Head; CXO; Manager; Senior Manager | Focus on decision makers and technical approvers. |
| Job titles | VP Pharmaceutical Sciences; Director Translational Sciences; Director Clinical Pharmacology; Head of Modeling & Simulation; Director DMPK; Director Formulation Development; Director Regulatory Science; Scientific Procurement Manager; Director Biomarkers; Business Development Director | Matches the published scientific themes and likely commercial pathways. |
| Geography | United States first; optional expansion to Canada, United Kingdom, Germany, Switzerland, and other mature pharma markets if international targeting is desired | Supports national event reach with optional global life-sciences expansion. |
| Employee size | 51–200; 201–500; 501–1,000; 1,001–5,000; 5,001+ | Captures biotech scale-ups through enterprise pharma organizations. |
| Keywords | translational science, clinical pharmacology, DMPK, ADME, PBPK, QSP, PK/PD, model-informed drug development, real-world data, organ-on-chip, microphysiological systems, biomarker, preclinical development, formulation development, AI/ML | Improves precision around the event’s published themes. |
| Technologies, if relevant | AI/ML, data analytics, simulation, scientific informatics, clinical data platforms | Useful where the client offers technical platforms or digital capabilities. |
| Revenue range, if relevant | Mid-market to enterprise for enterprise pharma; all revenue bands for research-led biotech | Balances commercial scale with innovation-stage buyers. |
| Company type | Public and private companies; research institutions; academic medical centers | Reflects the likely event audience mix. |
| Funding / public company filters, if relevant | Use funded biotech and public pharma filters for higher budget potential | Improves conversion focus for premium offerings. |
| Source | Type | What It Verified | Reliability |
|---|---|---|---|
| AAPS PharmSci 360 Official Event Page | Official organizer website | Confirmed event name, date, venue, city, state, registration activity, exhibitor/sponsor references, abstract/poster references, and major 2026 scientific themes. | Very High |
| American Association of Pharmaceutical Scientists (AAPS) Home | Official organizer website | Verified AAPS branding and organizational identity tied to PharmSci 360. | Very High |
| User-supplied official page content excerpt | Primary source text | Primary basis for extracting the exact confirmed dates, venue, and location without contradiction. | Very High |
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to American Association of Pharmaceutical Sciences - AAPS PharmSci 360 — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.